Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  • Home
Chapter
  • Print publication year: 2014
  • Online publication date: June 2014

13 - Premenstrual syndrome

Export citation

Summary

The surgical options for the management of menstrual problems are chiefly endometrial ablation as a uterine conserving procedure and either total or subtotal hysterectomy, which can be performed by a number of routes. Endometrial ablation represents the most thoroughly evaluated surgical treatment to date. Endometrial techniques are divided into first generation and second generation techniques. First generation techniques include transcervical resection of the endometrium (TCRE), rollerball endometrial ablation (RBEA), and endometrial laser ablation (ELA). They offer the benefit of direct vision and require a fluid distension media. Second generation techniques are: thermal balloon ablation, microwave endometrial ablation (MEA), NovaSure, Hydro ThermAblator, and cryosurgical ablation. Second-generation ablative techniques have been evolved to simplify the technique and ideally place endometrial ablation safely in the hands of all gynaecologists. Total hysterectomy is the only surgical treatment for menstrual problems that guarantees amenorrhoea. Satisfaction with hysterectomy is higher than that with ablation.

Keywords:

Related content

Powered by UNSILO

References

2. O’BrienS, RapkinA, DennersteinL et al. Diagnosis and management of premenstrual disorders. BMJ 2011;342;1297–303.
3. BMJ Point of Care/Best Practice: Premenstrual syndrome and dysphoric disorder [http://bestpractice.bmj.com/best-practice/welcome.html].
4. Royal College of Obstetricians and Gynaecologists. Management of Premenstrual Syndrome. Green-top Guideline No. 48. London: RCOG; 2007.
5. PotterJ, BouyerJ, TrussellJ, MoreauC. Premenstrual syndrome prevalence and fluctuation over time: results from a French population-based survey. J Womens Health (Larchmt) 2009;18:31–9.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders – DSM-IV. 4th ed. Washington DC: American Psychiatric Association; 1994.
7. O’BrienPM, BäckströmT, BrownC, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health 2011;14:13–21.
8. BorensteinJE, DeanBB, YonkersKA, EndicottJ. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol 2007;109:1068–75.
9. RossC, ColemanG, StojanovskaC. Factor structure of the modified Moos Menstrual Distress Questionnaire: assessment of prospectively reported follicular, menstrual and premenstrual symptomatology. J Psychosom Obstet Gynaecol 2003;24:163–74.
10. LandénM, NissbrandtH, AllgulanderC, SörvikK, YsanderC, ErikssonE. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007;32:153–61.
11. ShahNR, JonesJB, AperiJ, ShemtovR, KarneA, BorensteinJ. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008;111:1175–82.
12. SteinerM, RavindranAV, LeMelledoJM, et al. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. J Clin Psychiatry 2008;69:991–8.
13. TuccoriM, TestiA, AntonioliL, et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 2009;31:1426–53.
14. KielerH, ArtamaM, EngelandA, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2011;344:d8012.
15. LopezLM, KapteinA, HelmerhorstFM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2008;(1):CD006586.
16. FordO, LethabyA, MolB, RobertsH. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2006;(4):CD003415.
17. BusseJW, MontoriVM, KrasnikC, Patelis-SiotisI, GuyattGH. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom 2009;78:6–15.
18. Agha-HosseiniM, KashaniL, AleyaseenA, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG 2008;115:515–19.
19. GerhardsenG, HansenAV, KilliM, FornitzGG, PedersenF, RoosSB. The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study. Adv Ther 2008;25:595–607.
20. JingZ, YangX, IsmailKM, ChenX, WuT. Chinese herbal medicine for premenstrual syndrome. Cochrane Database Syst Rev 2009;(1):CD006414.